Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis MCQ — NEET PG Practice Question | NEETPGAI
Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis
medium
stethoscope Medicine
A 28-year-old woman with a 10-year history of focal seizures presents to the epilepsy clinic. She recalls febrile seizures at age 3, followed by a seizure-free period, then onset of impaired-awareness seizures at age 15 preceded by epigastric rising sensation and fear. Her seizures are refractory to levetiracetam and lacosamide at therapeutic doses. EEG shows the pattern marked **A** in the diagram — right anterior temporal sharp waves with phase reversal at F8/T4 electrodes. Brain MRI demonstrates right hippocampal atrophy with increased T2/FLAIR signal and loss of internal architecture on oblique-coronal cuts. Which of the following is the most appropriate next step in her management?
A. Referral for presurgical evaluation including video-EEG monitoring, neuropsychological testing, and language lateralization assessment
B. Initiation of a third anti-seizure medication (valproate) with repeat EEG in 3 months
C. Immediate right anterior temporal lobectomy with amygdalohippocampectomy
D. Vagal nerve stimulation implantation as a bridge to eventual surgical consideration
Explanation
Why option 1 (Referral for presurgical evaluation) is correct
The patient meets the ILAE definition of drug-resistant focal epilepsy (failure of two appropriately chosen, adequately dosed anti-seizure medications). The EEG pattern marked A — right anterior temporal sharp waves with phase reversal at F8/T4 — is the interictal hallmark of mesial temporal lobe epilepsy (MTLE) with hippocampal sclerosis (HS). Combined with the classic clinical history (febrile seizures in early childhood, silent period, then focal impaired-awareness seizures with epigastric aura and automatisms in adolescence) and MRI findings of unilateral hippocampal atrophy with T2/FLAIR signal abnormality, this is the prototype of a surgically remediable epilepsy syndrome. Per Harrison's and the landmark NEJM 2001 RCT by Wiebe et al, after failure of two appropriately chosen medications, patients should be referred for comprehensive presurgical evaluation (video-EEG, high-resolution MRI, neuropsychology, and WADA or fMRI for language/memory lateralization) to determine candidacy for anterior temporal lobectomy, which achieves seizure freedom in 60–70% at 2 years.
Why each distractor is wrong
Option 0 (Third anti-seizure medication): The patient has already failed two drugs at therapeutic doses and has imaging and EEG evidence of a surgically remediable lesion. Continuing medical therapy alone delays access to the only intervention proven superior to medical therapy in the Wiebe RCT. Escalating to a third drug is not the standard of care once drug-resistance is established in MTLE-HS.
Option 2 (Immediate temporal lobectomy): While anterior temporal lobectomy is the definitive treatment for drug-resistant MTLE-HS and does achieve high seizure-freedom rates, it cannot be performed immediately without first completing presurgical evaluation. Video-EEG monitoring, neuropsychological assessment, and language/memory lateralization (WADA or fMRI) are mandatory to confirm the seizure focus, assess surgical risk, and preserve cognitive function.
Option 3 (Vagal nerve stimulation): VNS is a palliative neuromodulation option for patients who are not candidates for resective surgery or who decline surgery. It is not the appropriate next step in a patient with clear evidence of a focal, surgically remediable lesion (unilateral hippocampal sclerosis with concordant EEG and clinical findings). VNS would delay access to curative surgery.
High-YieldNEET PG
MTLE-HS is the most common cause of drug-resistant focal epilepsy in adults and the prototype of a surgically remediable syndrome; anterior temporal sharp waves with phase reversal on EEG + unilateral hippocampal atrophy on MRI + drug-resistance = refer for presurgical evaluation, not escalate medical therapy.
Harrison's Principles of Internal Medicine, 21e; Wiebe et al NEJM 2001
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.